Prothena | PRTA - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Akebia Therapeutics USD 27.38M 5.24M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Exelixis USD 1.94B 225.57M 2026-03
Immunic USD 151.23M 157.91M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Prothena USD 312.62M 32.14M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Xoma USD 87.94M 15.5M 2025-09